Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2000-07-24
2003-03-25
Low, Christopher S. F. (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C514S021800, C514S559000, C514S706000, C514S707000, C514S851000, C514S861000, C514S863000, C514S912000, C530S328000, C530S350000, C424S493000, C424S491000, C435S183000, C435S219000
Reexamination Certificate
active
06537968
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to the treatment of lupus erythematosus. More specifically, there is provided the treatment of inflammatory conditions, rashes or lesions which occur with patients with systemic lupus erythematosus (SLE) by the administration of protease inhibitors.
BACKGROUND OF THE INVENTION
The common treatment for lupus erythematosus involves the H use of several drugs as well as sunscreens. Hydroxychloroquine alone or in combinations with oral steroids is used. Topical steroids and/or vitamin A are also used for treating skin eruptions. The patients with severe SLE involving several organs have been treated with immunosuppressive agents (corticosteroids and pulse cyclophosphamide therapy). The treatments have not been effective in many cases and have resulted in other problems resulting from an overuse of steroids.
In many cases, the presence of the skin lesions results in keloid scarring. The use of steroids not only does not prevent the scarring but can lead to thinning of the skin so as to lead to further lesions.
Systemic lupus erythematosus, is a chronic rheumatic disease in which connective tissue throughout the body becomes inflamed. It is an autoimmune disorder in which inflammation is caused by antibodies that attack normal body tissue as if it were an outside invader. The precise cause is unknown, but researchers believe that certain people inherit a genetic predisposition to the disorder, which is then triggered by a virus or some other unidentified environmental factor.
The disease strikes women about 10 times as often as men. It can develop at any age, but is most common in young adults. Symptoms range from so mild that SLE goes undetected for long periods to disabling, even life threatening.
Lupus is often described as the great pretender among Ad diseases because it causes such a wide range of symptoms, the most common of which are fatigue and joint pain. But other manifestations may include a chronic low-grade fever, hair loss, dry eyes and mouth, muscle aches, swollen lymph nodes, loss of appetite, nausea, and mouth ulcers.
About half of all patients develop a butterfly-shaped rash over the nose and cheeks. Depending upon the organs affected, SLE may also cause severe headaches, anemia, inflammation in the lining of the heart or lungs, kidney failure, and mental disorders.
A variation—discoid lupus erythematosus—affects mainly the skin. A rash may appear not only on the face but also on the neck, scalp, and other areas. It ranges from a mild scaliness to a widespread blistery eruption.
As in many other rheumatic disorders, symptoms come and go unpredictably. Sun exposure or stress often produces a flare-up. During pregnancy, symptoms can worsen and cause miscarriage.
It has now been found that mast cells play a role in the formation of the lesions and inflammation. The presence of cathepsin G and elastase in excess results in the poor laying down of tissue so as to result in scarring. The swollen joints result from an inflammatory condition.
Alpha 1-antitrypsin (AT) belongs to the serpin superfamily of serine protease inhibitors. It is a small glycoprotein which is mostly synthesized in the liver and has a molecular weight of 53,000 daltons. Human proteinase inhibitors are involved in the regulation of proteolysis, such as the coagulation pathway, fibrinolysis, tissue destruction by endogenous serine proteinases and inflammation.
U.S. Pat. No. 5,492,889 to Lezdey et al, which is herein incorporated by reference, disclosed the treatment of mast cell tumors by the administration of alpha 1-antitrypsin alone or in combination with other serine protease inhibitors.
SUMMARY OF THE INVENTION
The present invention provides a method of treating lupus erythematosus and more particularly to skin eruptions and inflammations resulting from the disease.
According to one embodiment of the invention, there is provided the treatment of symptoms of lupus erythematosus, and in particular, the administration of a serine protease inhibitor. More specifically, according to one embodiment, the treatment provides topically applying a composition containing an effective amount of a serine protease inhibitor selected from the group consisting of alpha 1-antitrypsin, secretory leucocyte protease inhibitor (SLPI), alpha 2-macroglobulin and mixtures thereof to the site of the disease.
Advantageously, the composition includes an effective amount of arginine or an arginine containing amino acid to help in penetration of the drug into the skin.
According to another embodiment of the invention there is provided the treatment of individuals having a lupus disease associated with skin eruptions by treatment with protease inhibitors which prevent the degranulation of mast cells, controls the levels of tryptase, prevent or control the release of histamine and prevent scarring. The treatment includes providing a composition for topical administration. Preferably, a combination therapy is used to treat both the disease and the symptoms.
It is a general object of the invention to provide a composition and method for treating lupus erythematosus.
It is a further object of the invention to prevent scarring by individuals with SLE.
It is yet another embodiment to treat the inflammation which results in patients with SLE.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
In accordance with one embodiment of the invention, there is provided a method for the treatment of individuals suffering from lupus erythematosus or symptoms thereof by the administration of a serine protease inhibitor. The method consists of the administration of an effective therapeutic amount of a protease inhibitor selected from the group consisting of alpha 1-antitrypsin, secretory leucocyte, protease inhibitor, alpha 2-macroglobulin or mixtures thereof, and analogs or derivatives thereof in a suitable pharmaceutical carrier.
Accordingly, a composition containing about 0.5 to 10 mg. of protease inhibitor is in a suitable pharmaceutical vehicle is used in the treatment. Generally, for topical use, about 1 to 5 mg. of the protease inhibitor has been effective to treat the eruption and to prevent scarring.
Preferably, about 1 to 5 mg of the protease inhibitor in its natural, transgenic or recombinant form is placed into a composition for topical application such as a cream, gel, ointment or the like. A corticosteroid may be included in the treating composition. The treatment provides immediate relief of pain since the kinins and kallikreins can be controlled. The patient can be treated daily until the lesions are reduced and under normal bodily control. In severe cases, oral corticosteroids may be utilized. The composition may also include penetrating agents such as hyaluronic acid, insulin, liposome, or the like, as well as L-arginine or the arginine containing amino acids. The penetrants may be used in an amount of about 0.5 to 2% by weight of composition. Hyaluronic acid also aids in wound healing.
Systemic lupus erythematosus may also be treated by weekly infusion of 200 mg of the serine protease inhibitor in a 2% saline solution or by oral dosages daily of the inhibitor in a carrier which transgresses the gastric barrier.
It has been found that the incorporation of L-arginine or an arginine containing amino acid having up to ten carbon atoms helps in the penetration of the drug into the skin. The arginine also attracts hormones to the site to help in wound healing.
Serine protease inhibitors have been found to play a major role in the direct inactivation of the mediators of inflammation. The almost immediate disappearance of pain indicates that there can be a control of the kinins as well. A cocktail of serine protease inhibitors, their analogs, salts or derivatives, appears to provide the quickest healing when used in combination with a corticosteroid.
The drug can be administered topically in unit dosage form containing about 1 to 5 mg per day depending on the severity of the disease. The use of controlled release substances, for example, liposomes, diketopyperazine microparticles as disclosed
Lezdey Darren
Lezdey Jarett
Alphamed Pharmaceuticals Corp
Kam Chih-Min
Lezdey John
Low Christopher S. F.
LandOfFree
Treatment of lupus erythematosus does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of lupus erythematosus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of lupus erythematosus will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3067453